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NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Background  30 
The role of specific blood tests to predict poor prognosis in patients admitted with infection from 31 
SARS-CoV2 virus remains uncertain. During the first wave of the global pandemic, an extended 32 
laboratory testing panel was integrated into the local pathway to guide triage and healthcare 33 
resource utilisation for emergency admissions. We conducted a retrospective service evaluation to 34 
determine the utility of extended tests (D-dimer, ferritin, high-sensitivity troponin I, lactate 35 
dehydrogenase, procalcitonin) compared to the core panel (full blood count, urea & electrolytes, 36 
liver function tests, C-reactive protein).  37 
Methods 38 
Clinical outcomes for adult patients with laboratory-confirmed COVID-19 admitted between 17
th
 39 
March to 30
st 
June 2020 were extracted, alongside costs estimates for individual tests. Prognostic 40 
performance was assessed using multivariable logistic regression analysis with 28-day mortality used 41 
as the primary endpoint, and a composite of 28-day intensive care escalation or mortality for 42 
secondary analysis.  43 
Results 44 
From 13,500 emergency attendances we identified 391 unique adults admitted with COVID-19. Of 45 
these, 113 died (29%) and 151 (39%) reached the composite endpoint. “Core” test variables adjusted 46 
for age, gender and index of deprivation had a prognostic AUC of 0.79 (95% Confidence Interval, CI: 47 
0.67 to 0.91) for mortality and 0.70 (95% CI: 0.56 to 0.84) for the composite endpoint. Addition of 48 
“extended” test components did not improve upon this.  49 
Conclusion 50 
Our findings suggest use of the extended laboratory testing panel to risk stratify community-51 
acquired COVID-19-positive patients on admission adds limited prognostic value. We suggest 52 
laboratory requesting should be targeted to patients with specific clinical indications. 53 
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Introduction:  55 
In December 2019, a novel coronavirus disease (COVID-19) was reported in China, caused by severe 56 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). In the first 8 months since its 57 
emergence, SARS-CoV-2 has caused over 32 million infections and more than a million deaths 58 
worldwide (2). The majority of patients with COVID-19 experience a mild influenza-like illness, 59 
however approximately 15-25% of those admitted to hospital develop pneumonia that may evolve 60 
into acute respiratory distress syndrome (ARDS) (3-6). Experience from the Italian region of 61 
Lombardy highlighted the potential of uncontrolled COVID-19 outbreaks to rapidly overwhelm local 62 
intensive care capacity and healthcare systems (5). In the United Kingdom, Wales has one of the 63 
lowest number of intensive care beds per head of population in Europe (7, 8), prompting 64 
implementation of scoring systems to support patient triage and allocation of healthcare resources.  65 
The ability to identify patients at greatest risk of developing life-threatening complications from 66 
SARS-CoV-2 infection based on haematological and biochemical laboratory markers was suggested 67 
early in the pandemic. A range of admission tests including D-dimer, ferritin, high-sensitivity 68 
troponin I (hs-Trop), and lactate dehydrogenase (LDH) have been linked with disease severity and 69 
risk of death (9-13). Similar findings have been replicated in meta-analysis (14).  Furthermore, use of 70 
a broader range of laboratory tests in patients with COVID-19 has been supported by the UK Royal 71 
College of Pathologists (15). Accordingly, an extended panel of laboratory tests was integrated 72 
within the standard of care pathway for COVID-19 admissions presenting via the Emergency 73 
Department (ED) of the University Hospital of Wales. This panel consisted of both “core” (full blood 74 
count, FBC; urea & electrolytes, U&E; liver function tests, LFTs; C-reactive protein, CRP) and 75 
“extended” test components (D-dimer; LDH; ferritin; hs-Trop; and procalcitonin, PCT).  76 
A joint National Health Service (NHS)-University collaboration supporting the rapid creation of an 77 
electronic healthcare registry (see extended methods) provided a timely opportunity to 78 
retrospectively assess the value and cost of implementing this extended laboratory panel. This is 79 
particularly relevant given a recent systematic review of methodological and reporting standards 80 
highlighting caution before extrapolating models and decision thresholds derived from prognostic 81 
biomarker studies into local clinical practice (18). The role of extended components remains poorly 82 
represented in prognostic studies within the UK population to date (4, 16-19). We therefore 83 
conducted a service evaluation focusing on the ability of these tests to predict mortality or 84 
escalation to intensive care in the first 28-days following admission, in adult patients with PCR-85 
confirmed COVID-19. Our primary aim was to assess how addition of components of the extended 86 
panel altered the prognostic performance of the core panel (15). Our secondary aim was to explore 87 
the additional cost of extended testing components. Together, this directs refinement of a risk 88 
stratification panel with potential cost savings ahead of future waves of COVID-19.  89 
 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted October 15, 2020. .https://doi.org/10.1101/2020.10.06.20205369doi: medRxiv preprint 
Methods 90 
Study population 91 
We identified patients aged ≥ 18 years admitted between 17
th
 March 2020 to 30
th
 June 2020 via the 92 
Emergency Department (ED) of the University Hospital of Wales (Cardiff, UK). This 1,000-bed 93 
hospital is a tertiary referral centre within the region with the greatest recorded total of COVID-19 94 
case positives in Wales (20). Only patients with SARS-CoV-2 infection confirmed by positive reverse 95 
transcriptase polymerase chain reaction (PCR) on nasopharyngeal swab, and likely community-96 
acquired disease (defined as swab positive between 14 days prior or 7 days following the date of 97 
initial emergency attendance) were included. Patients transferred in from other hospitals were 98 
excluded.  99 
The primary dataset was extracted as part of a service evaluation to assist local care planning. A fully 100 
anonymised dataset was created by a member of the Health Board NHS IT team. Prior to 101 
anonymisation, the postcode was used to extract the Welsh Index of Multiple Deprivation (WIMD) 102 
for each patient, as obtained from https://wimd.gov.wales/. As such, ethical approval was not 103 
required for this study.  104 
Data fields including admission date, clinical outcomes, and laboratory measurements were 105 
integrated into an electronic healthcare registry “Cardiff Hospital Admissions Database” (CHAD) 106 
using a bespoke software package: CHADBuilder (see extended methods). Laboratory test results 107 
from the index presentation reported within the first 72 hours of ED presentation were considered 108 
as candidate variables.  109 
Outcomes  110 
28-day mortality was chosen as the primary endpoint in accordance with UK COVID-19 mortality 111 
reporting. To support generalisability between studies (4, 16) we performed secondary analysis 112 
using the composite endpoint of 28-day mortality or admission to intensive care.  113 
Laboratory testing panel 114 
All testing was performed in the United Kingdom Accreditation Service (UKAS)-accredited 115 
Biochemistry, Immunology, and Haematology Laboratories at the University Hospital of Wales. Cost 116 
estimates were obtained from the Health Board Laboratory Medicine Directorate, reflecting 117 
consumables, reagent, analyser running and maintenance costs, and staff time chargeable to NHS 118 
test requestors.  119 
Statistical analysis 120 
Statistical significance testing was performed according to the data encountered: for categorical 121 
data, such as gender, Fisher’s exact or chi-square testing was performed. For continuous data, 122 
Welch's t-tests were used if the assumptions of normality were met; otherwise non-parametric 123 
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Mann-Whitney U tests were employed. In edge-cases, permutation testing was performed. Two-124 
sided statistical significance was set at p <0.05, with Bonferroni correction for multiple testing. 125 
Model development 126 
Candidate laboratory variables were triaged for inclusion based on their membership of core or 127 
extended laboratory test panels, before a data-driven approach was applied. This included 128 
assessment of variability, individual p-values corrected for multiple comparisons and multi-129 
collinearity with generation of a Spearman's rank correlation matrix.  130 
Logistic regression, support vector machines, random forest, and gradient boosted trees were all 131 
considered for multivariate predictive models. Models with complexity greater than logistic 132 
regression were found to offer little improvement (data not shown). Multivariate logistic regression 133 
was implemented in Python (version 3.7) using the Scikit-Learn package (version 0.23) (21) and 134 
Statsmodels (version 0.11). Complete case analysis was conducted to enable meaningful comparison 135 
between core and extended tests. 136 
To minimise bias, models were evaluated using cross-validation with 5-folds, with stratification to 137 
account for class imbalance. Performance statistics are reported as the average across all folds with 138 
binomial proportion 95% confidence intervals. Model discrimination was assessed by area under 139 
receiver operating characteristic curve (ROC AUC), accuracy (balanced by support) and weighted F1 140 
score (the average F1 score was calculated for each class and weighted by support). In addition to 141 
these performance metrics, threshold-performance curves were generated to assess the effect of 142 
the decision threshold on model sensitivity and specificity (22). Source code for all models can be 143 
found on GitHub: https://github.com/burtonrj/CardiffCovidBiomarkers  144 
Our evaluation is reported using the transparent reporting of a multivariable prediction model for 145 
individual prognosis or diagnosis (TRIPOD) guidance for Prediction Model development and 146 
validation (See Appendix). 147 
Patient involvement 148 
These data were generated as part of a rapid service improvement and as such patients were not 149 
involved in the setting of the research question or interpretation of the study.  150 
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Results 151 
Definition and overview of service evaluation cohort 152 
We focused on admissions occurring after the operational roll-out of the first extended laboratory 153 
test panel components into standard clinical practice. During this 105 day period, over 13,500 ED 154 
attendances were recorded. Of these, 391 adults were admitted via ED with a laboratory-confirmed 155 
diagnosis of COVID-19 meeting our definition of likely community-acquired COVID-19 (Figure 1: 156 
Study Flowchart). The median age was 69 years (interquartile range, IQR: 55 - 75 years) with males 157 
predominant (52.4%). Within 28-days of index ED attendance, 113 deaths occurred (29% mortality), 158 
and 151 patients reached the composite secondary endpoint of intensive care admission/death 159 
(39%).  160 
Univariate analysis of laboratory predictors of adverse inpatient course    161 
We next analysed the association between individual candidate variables and patient outcomes to 162 
identify important predictors of adverse outcome. Admission clinical variables are presented in 163 
Table 1 (for full dataset, Supplementary S1&S2). Advanced age was strongly associated with 164 
increased risk of death and the composite of ICU admission and death. In contrast, neither gender 165 
nor socio-economic deprivation were associated with 28-day mortality. For laboratory variables, 166 
missing data were rare for core test panel components. Within the extended testing panel, hs-Trop 167 
and D-dimer were available in 70-80% of patients admitted with COVID-19 within the first 72 hours 168 
of ED attendance. An early admission PCT test result was available in 40% of patients, whilst ferritin 169 
and LDH levels were recorded in 42-46% of cases. Testing rates were similar between patient 170 
survival groups. 171 
In univariate analysis of the core laboratory panel components, increased CRP, 172 
neutrophil:lymphocyte ratio, urea, creatinine; or decrease in serum albumin were all strongly 173 
associated with risk of death. Within the extended panel, D-dimer, hs-Trop and PCT differed 174 
between survivors and non-survivors on univariate analysis (Figure 2; Supplementary S3). No 175 
extended panel members were associated with development of the composite outcome 176 
(Supplementary S4&S5). Age was associated with several variables (Supplementary S6), indicating it 177 
could confound the relationship between a test result and mortality.  178 
Development of prognostic model based on core and extended laboratory admission test panels 179 
We therefore used multivariate logistic regression to adjust for the role of age, whilst controlling for 180 
gender and WIMD, based on consistent identification of their contribution to outcomes in COVID-19 181 
cohorts (23, 24). Restricting to cases with complete data (n=130) across core and extended 182 
laboratory tests, we found an optimal combination of core test variables to be CRP, albumin, urea, 183 
neutrophil:lymphocyte ratio, creatinine, age, gender and WIMD (Figure 3, Supplementary S7). This 184 
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gave a prognostic AUC of 0.79 (95% confidence interval, CI: 0.67 to 0.91) for 28-day mortality, and 185 
0.70 (95% CI: 0.56 – 0.84) for the composite outcome. 186 
We next assessed the discriminative value associated with inclusion of extended panel components 187 
within our multivariate model, relative to this core test set (Figure 5). Addition of D-dimer resulted 188 
in a marginal increase in mean AUC score to 0.82, but this was not significantly different (95% CI: 189 
0.71 – 0.85) to the performance of core testing alone. Concerning the composite outcome, addition 190 
of admission hs-Trop to the core panel resulted in the greatest AUC score: 0.72 (95% CI: 0.60 to 0.83) 191 
but again, this did not represent a significant increase in performance to the core panel alone 192 
(Supplementary S7&S8). Consideration of extended test components individually or in combination 193 
did not improve upon this. To internally validate these findings, we performed stratified cross-194 
validation, observing convergence of training and validation curves, thus suggesting a low-risk of 195 
over-fitting associated with these models (Supplementary S9&S10). Assessing the calibration of 196 
these models across a range of performance metrics by varying the decision threshold (the 197 
probability at which a patient is predicted to either die or be admitted to intensive care), we found 198 
no significant benefit from addition of the extended relative to the core laboratory testing panel 199 
(Supplementary S11&12).  200 
 201 
Patterns of extended panel requesting during the first wave 202 
Local cost estimates for NHS requesting the core laboratory panel totalled £16.44 per patient, with 203 
an additional £55.48 incurred for the extended set (Supplementary S13). In order to contextualise 204 
testing beyond the cohort of community-acquired COVID-19, we constructed a run-chart of test 205 
requesting within the first 72 hours of admission via ED and COVID-19-related admissions (Figure 4). 206 
D-dimer and hs-Trop testing rates rose in line with COVID-19 admissions during March and April, 207 
with a 1-2 week delay apparent for LDH, ferritin, and PCT requesting. Strikingly, whilst COVID-19 208 
admissions declined following the April peak, the intensity of extended biomarker panel requesting 209 
remained. Using January and June 2020 to represent requesting patterns before and after the first 210 
wave of COVID-19, mean monthly requesting increased by 29.7%, 224%, and 588% for hs-Trop, 211 
ferritin, and LDH, respectively. In contrast, recorded monthly ED attendance fell by 24.0% over this 212 
period. PCT and quantitative D-dimer were specifically introduced in response to the pandemic, but 213 
still averaged >50 daily test requests within the early admission period during June. Across the 214 
evaluation period, over 6,400 D-dimer and 5,400 PCT requests were made, with an estimated service 215 
cost of £246,000.  216 
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Discussion 218 
To support the effective and efficient use of resources through evidence-based clinical practice, we 219 
conducted a service evaluation determining the prognostic value associated with routinely 220 
performed laboratory investigation in 130 adults admitted with community acquired SARS-CoV-2 221 
infection. By leveraging a bespoke electronic healthcare registry, we reveal an extended panel 222 
(including D-dimer, LDH, hs-Trop, ferritin, PCT) provided only limited additional prognostic 223 
information beyond that provided by components of the core panel (FBC, U&E, LFT, and CRP). 224 
Together, this directs refinement of the clinical testing panel employed before and during future 225 
potential waves, underlining the relevance of this registry-approach to support cost-utility of 226 
investigation pathways. 227 
We identified 5 studies within the peer-reviewed and pre-print literature concerning laboratory 228 
biomarker risk stratification of adult COVID-19 admissions in the UK population (4, 16-19). The 229 
largest reported, an 8-point pragmatic risk score developed by the ISARIC Consortium, achieved a 230 
modest AUC performance score of 0.77 (95% CI 0.76 to 0.77) when predicting 28-day mortality (18). 231 
To date, only 1 UK study has considered the prognostic role of variables within our extended 232 
laboratory panel (16). In their prospective analysis of 155 patients, Arnold et al. found conventional 233 
laboratory biomarkers such as CRP and neutrophil elevation offered limited prognostic performance 234 
(with AUC scores of 0.52 and 0.54, respectively), whilst ferritin, PCT, hs-Trop, and LDH performed 235 
with AUC scores of 0.65 to 0.71. It is important to note that within this study cohort, the incidence of 236 
clinical deterioration was low (overall mortality was only 4% vs 29% for our service evaluation) which 237 
may have limited the power of the study (16). This highlights regional variation in rates of 238 
hospitalisation and mortality, and further motivated a locally-led assessment of practice.  239 
Consistent with the emerging COVID-19 literature, we observed an association between laboratory 240 
markers of acute phase inflammatory response (elevated neutrophil count, CRP; depressed 241 
lymphocytes and albumin), cardiac injury, activation of thrombosis, and renal impairment with  242 
subsequent adverse outcome (6, 23, 25). We found a combination of CRP, albumin, urea, 243 
neutrophil:lymphocyte ratio, and creatinine alongside simple demographics achieved an AUC of 0.79 244 
(95% CI: 0.67 – 0.91) when predicting 28-day mortality, and 0.70 (95% CI: 0.56 – 0.84) for the 245 
composite endpoint. We found no evidence that use of this panel at admission significantly 246 
improved performance for either outcome. Importantly, we identified use of the extended 247 
laboratory panel continued despite falling rates of COVID-19 presentations, indicating a change in 248 
routine test requesting patterns. Addition of the extended laboratory test panel equates to £54 per 249 
patient (a relative cost increase of over 400% to the core panel alone), with significant cost 250 
ramifications when performed at scale.  251 
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Our service evaluation has several strengths, notably assessment of the performance of an extended 252 
panel of laboratory tests not widely considered in UK prognostic studies to date (4, 16-19). These 253 
tests were integrated into routine practice prior to the local peak of the pandemic, based on 254 
available literature and national guidelines (15). In contrast with the batched analysis undertaken 255 
under research condition in previous studies (16), all tests described here were conducted by 256 
accredited laboratories using platforms calibrated to international reference standards, facilitating 257 
future data sharing. Our multivariate approach is well-suited to investigate whether specific 258 
laboratory tests provide additional prognostic value beyond conventional parameters (26), using 259 
inclusion criteria and clinically-relevant endpoints in line with other reported studies (4, 17, 18). 260 
Finally, we considered the service costs that accompanied implementing these tests into routine 261 
practice (27), a relevant factor often neglected in other publications.  262 
Our evaluation also has a number of limitations, reflecting the challenges of clinical data collection 263 
during an epidemic. It represents retrospective experience from a single tertiary referral centre, 264 
limiting sample size and the generalisability of our findings. Secondly, availability of extended test 265 
panel results during the early admission period was mixed. Admission D-dimer and hs-Trop results 266 
were available for 70-80% of patients, comparing favourably to a similar UK registry-based study 267 
where D-dimer results were only available at time of admission in 37.2% (17). Conversely, we 268 
observed high rates of missing data for LDH, ferritin, and PCT, undermining their relevance as a 269 
prognostic tool. This was likely due to operational factors such as a delay in test roll out relative to 270 
epidemic peak, and requirement for an additional sample tube. Because it cannot be assumed that 271 
data are missing at random, we chose to perform complete case analysis. Although this limits our 272 
statistical power, it avoids unfounded assumptions and potentially invalid imputation. In its current 273 
form, the CHAD-registry lacks detailed information on patient-level physiological observations, 274 
nature of co-morbidities, and therapeutic interventions. Similarly, all registry-linked laboratory 275 
values were available to clinicians, and are likely to have influenced management decisions. With 276 
advances in clinical care diagnostics, therapeutics are likely to alter the observed performance of the 277 
prognostic model. These limitations apply equally to pragmatic risk-scores (4, 16, 18). Finally, we 278 
recognise our evaluation consider the index test result and a specific question of inpatient prognosis, 279 
and additional indications exist for requesting components of the extended laboratory tests that fall 280 
outside of our primary and secondary endpoints. For instance, the use of PCT is often employed to 281 
support antibiotic stewardship (28), and was integrated into routine practice locally in early April 282 
2020. There may also be merit in more targeted use of additional testing particularly as therapeutic 283 
options evolve. Hence, whilst we highlight the significant associated healthcare costs with 284 
implementation of extended laboratory testing, we do not make specific claims concerning the 285 
potential savings from discontinuing unnecessary investigations (27). 286 
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Implications for practice 287 
Laboratory markers supporting early risk stratification of patients are often used in the ED setting, 288 
and have been shown to benefit patient triage (29). Our data suggest that systematic testing of 289 
COVID-19-positive patients upon admission with an “extended” laboratory panel provide little 290 
additional prognostic information for COVID-19 mortality or intensive care admission “core” tests. 291 
Besides the financial impact, over-requesting of laboratory tests are likely to increase the number of 292 
false-positive results, with the potential to lead to further potentially harmful tests (e.g. computed 293 
tomography pulmonary angiography in patients with marginally elevated D-dimer but no clinical 294 
indication of thromboembolic disease) (30). We suggest that the use of these laboratory markers be 295 
targeted to patients with specific clinical indications for these, such as PCT to guide antibiotic 296 
prescription or hs-Trop in patients with suspected myocardial injury. 297 
In conclusion, we report our real-world experience from the use of an extended laboratory 298 
prognostic testing panel in patients hospitalised with community-acquired COVID-19. These findings 299 
directly inform clinical practice, guiding cost-efficient use of resources in potential future waves.  300 
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Data sharing 302 
Requests for data sharing will be reviewed by a clinical and information regulatory governance panel 303 
and considered on an individual basis. 304 
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Key Messages 333 
 334 
During the first wave of the pandemic, the literature and guidance from the UK Royal College of 335 
Pathologists supported the use of extended biochemistry and haematology testing upon admission 336 
to support risk stratification of patients with COVID-19 infection- however the prognostic 337 
performance of these markers remains unclear. 338 
 339 
Our service evaluation suggests that systematic testing of COVID-19-positive patients with likely 340 
community-acquired disease upon admission with an “extended” laboratory panel (high-sensitivity 341 
Troponin I, Ferritin, Lactate Dehydrogenase, procalcitonin, or quantitative D-dimer) provides limited 342 
additional prognostic information for 28-day mortality or intensive care admission, relative to 343 
conventional “core” tests such as a full blood count, renal function, C-reactive protein combined 344 
with simple demographics. 345 
 346 
Few clinicians know the cost of the tests they request for their patients. With individual “extended” 347 
panel members costing over £20 per test, and thousands of tests requested per month within a 348 
single hospital, these costs quickly escalate.  349 
 350 
Besides the financial impact, over-requesting of laboratory tests are likely to increase the number of 351 
false-positive results, with the potential to lead to further potentially harmful investigations (e.g. 352 
computed tomography pulmonary angiography in patients with marginally elevated D-dimer but no 353 
clinical indication of thromboembolic disease). We suggest that the use of these laboratory markers 354 
be targeted to patients with specific clinical indications for these, such as procalcitonin to guide 355 
antibiotic stewardship or hs-Troponin I in patients with suspected myocardial injury.  356 
 357 
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Table 1: Demographic and selected clinical laboratory predictor variables on 441 
admission for evaluation cohort.  442 
Variables captured in the summarised cohort of community-acquired PCR-confirmed COVID-19 cases 443 
admitted through the ED between 17
th
 March 2020 and 30
th
 June 2020. Summary statistics are given 444 
as the median and range for continuous variables and absolute counts for discrete variables. * Welsh 445 
index of multiple deprivation, WIMD, is ranked from 1 (most deprived) to 1,909 (least deprived), and 446 
presented as frequencies within each quartile. †Fischer’s exact test.  447 
 448 
 Survivors (n= 278) Non-survivors (n=113)  
Variable Frequency % 
Missing 
Frequency % Missing p-value 
Gender  0  0  
Male 141 (50.7%) - 64 (56.6%) - 0.316† 
Female 137 (49.3%) - 49 (44.4%) -  
WIMD*  2.52  0.885 0.228† 
Quartile 1 (< 246) 65 (23.4%) - 29 (25.6%) -  
Quartile 2 (246 – 871) 61 (21.9%) - 35 (31.0%) -  
Quartile 3 (872 – 1672) 73 (26.3%) - 23 (20.4%) -  
Quartile 4 (> 1672) 72 (25.9%) - 25 (22.1%) -  
      
 Median [IQR]  Median [IQR]   
Age, years 63.5 [51.25 - 77.75] 0 81.0 [71.0 - 88.0] 0 < 0.0001 
      
“Core” test component   Median [IQR]   
Albumin, g/L 33.0 [29.0 - 36.0] 3.24 29.0 [26.0 - 32.0] 1.77 < 0.0001 
Alkaline phosphatase U/L 80.0 [63.0 - 111.5] 0.04 100.0 [76.0 - 133.5] 0.02 0.0006 
Alanine transaminase U/L 27.0 [17.0 - 46.0] 0.04 23.0 [14.0 - 32.0] 0.02 0.256 
Bilirubin μmol/L 10.0 [7.0 - 15.0] 0.04 12.0 [8.0 - 17.0] 0.02 0.0018 
C-reactive protein, mg/L 70.5 [21.0 - 131.75] 0.00 98.0 [55.75 - 164.75] 2.65 0.005 
Creatinine, µmol/L 82.0 [66.0 - 105.0] 0.36 111.0 [79.0 - 192.0] 0.00 < 0.0001 
Estimated GFR ml/min/1.73m
2
 75.0 [55.0 - 89.0] 0.01 51.0 [25.0 - 74.0] 0.00 < 0.0001 
Globulin g/L 38.0 [34.0 - 42.0] 0.07 40.0 [36.0 - 45.75] 0.06 0.0161 
Haemoglobin g/L 135.0 [122.0 - 149.0] 0.00 135.0 [122.0 - 149.0] 0.00 0.036 
Lymphocyte count x10
9
/L 1.0 [0.7 - 1.4] 0.00 0.9 [0.6 - 1.22] 0.01 0.961 
Neutrophil count x10
9
/L 5.4 [3.7 - 7.98] 0.00 7.3 [4.57 - 9.8] 0.01 0.017 
Neutrophil : Lymphocyte ratio 5.25 [3.25 - 9.81] 0.36 8.11 [4.34 - 14.53] 0.88 0.011 
Platelet count x10
9
/L 234.0 [183.75 - 294.5] 0.00 216.0 [160.0 - 285.0] 0.00 0.210 
Potassium mmol/L 3.9 [3.6 - 4.3] 0.01 4.1 [3.73 - 4.6] 0.03 0.0006 
Protein g/L 71.0 [67.0 - 76.0] 0.07 70.0 [65.0 - 74.0] 0.06 0.04 
Sodium mmol/L 137.0 [134.0 - 139.0] 0.00 138.0 [134.0 - 141.0] 0.00 < 0.0001 
Urea mmol/L 5.7 [4.0 - 8.5] 0.36 10.2 [7.2 - 16.2] 0.00 < 0.0001 
White blood cell count x10
9
/L 7.35 [5.3 - 9.93] 0.00 9.0 [6.4 - 12.3] 0.00 0.016 
“Extended” test component      
Ferritin μg/L 325.0 [125.0 - 828.0] 57.9 482.0 [245.5 - 993.5] 54.9 0.395 
High sensitivity D-dimer  μg/L 926.5 [587.75 - 1750.0] 28.1 1497.0 [929.0 - 3885.0] 30.1 0.0003 
High Sensitivity Troponin I 
ng/L 
7.0 [3.0 - 23.0] 24.8 35.5 [15.75 - 117.0] 22.1 < 0.0001 
Lactate dehydrogenase U/L 349.5 [270.25 - 549.75] 53.2 383.5 [290.5 - 501.25] 54.0 0.999 
Procalcitonin μg/L 0.14 [0.06 - 0.38] 41.4 0.31 [0.09 - 0.86] 38.9 0.019 
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Figure 1: Study Flowchart 449 
 450 
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Figure 2: Laboratory test results according to survival outcome and grouped by 452 
gender 453 
Caption: Box and swarm plots showing the initial laboratory test results from laboratory-confirmed 454 
COVID-19 patients, grouped by gender and 28-day mortality. Example variables considered from the 455 
components of the core laboratory test panel. * indicates level of significance, assessed by Mann-456 
Whitney U test with correction for multiple testing:  * p<0.05, ** p<0.01, *** p<0.005. **** p <0.001. 457 
 458 
 459 
 460 
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Figure 3: Balanced accuracy (A), weighted F1 score (B), AUC score (C) and ROC 461 
curves (D) for models with sequential inclusion of extended biomarkers for prediction 462 
of 28 day mortality 463 
  464 
A 
C 
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Figure 4: Daily COVID-19 admission rates and test requesting patterns during the 465 
early admission period  466 
 467 
Caption: Run-chart showing Emergency Unit (ED) admission rates for patients with confirmed 468 
laboratory-confirmed COVID-19 (right y-axis, black), and accompanying tests performed within 72 469 
hours of ED attendance (left y-axis, blue) during the first wave of the COVID-19 pandemic. The dotted 470 
line indicates the roll-out of extended panel testing from 17
th
 March 2020. 471 
472 
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